CannabisNewsBreaks – InMed Pharmaceuticals Inc. (NASDAQ: INM) Reports on Promising Results from Study on INM-089 Treatment of Dry AMD

Company: InMed Pharmaceuticals Inc. (INM)
Category: News

InMed Pharmaceuticals (NASDAQ: INM), a leader in the research, development, manufacturing and commercialization of rare cannabinoids and proprietary cannabinoid analogs, is reporting on additional preclinical data for INM-089, a proprietary small molecule compound acting as a preferential signaling ligand of cannabinoid receptor 1 (“CB1”) and cannabinoid receptor 2 (“CB2”). The reported data continues to demonstrate positive pharmacological effects in the treatment of dry age-related macular degeneration (“AMD”). According to the announcement,

in vivo preclinical studies in AMD disease models show that INM-089 delivers improved retinal pigment epithelium integrity, neuroprotection and photoreceptor improvement. Earlier results showed that INM-089 also preserved retinal function and improved the thickness of the outer nuclear layer of the retina, where photoreceptors are located. “We are very excited with the data from recent preclinical studies demonstrating both significant functional and pathological improvements from INM-089 in the AMD model,” said InMed Pharmaceuticals SVP of preclinical research and development Dr. Eric Hsu in the press release. “While a few treatment options are currently available, their efficacy is limited and may be associated with several undesirable side effects. We see an opportunity for INM-089 to slow the progression and to fill a significant gap in the treatment of this chronic disease.”

To view the full press release, visit https://cnw.fm/K23zX

About InMed Pharmaceuticals Inc.

InMed Pharmaceuticals is a global leader in the manufacturing, development and commercialization of rare cannabinoids and proprietary cannabinoid analogs. The company is a clinical-stage company developing a pipeline of proprietary cannabinoid-analog therapeutics and dedicated to delivering new treatment alternatives to patients who may benefit from cannabinoid-based pharmaceutical drugs. For more information, please visit www.InMedPharma.com.

NOTE TO INVESTORS: The latest news and updates relating to INM are available in the company’s newsroom at https://cnw.fm/INM

About CanadianCannabisWire

CanadianCannabisWire (“CNW”) is a specialized communications platform with a focus on cannabis news and the Canadian cannabis sector. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, CNW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, CNW brings its clients unparalleled recognition and brand awareness. CNW is where breaking news, insightful content and actionable information converge.

To receive SMS alerts from CanadianCannabisWire, text “CCWIRE” to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.CanadianCannabisWire.com

Please see full terms of use and disclaimers on the CanadianCannabisWire website applicable to all content provided by CNW, wherever published or re-published: www.CanadianCannabisWire.com/Disclaimer

CanadianCannabisWire
Toronto, ON
www.CanadianCannabisWire.com
905.674.5977 Office
Editor@CanadianCannabisWire.com

CanadianCannabisWire is powered by IBN

CanadianCannabisWire Currently Accepts

Bitcoin

Bitcoin

Bitcoin Cash

Bitcoin Cash

Doge Coin

Dogecoin

Ethereum

Ethereum

Litecoin

Litecoin

USD Coin

USD Coin

Contact us: 905.674.5977